The overall risk for biochemical recurrence of prostate cancer after radical prostatectomy increased by a significant 15% after 2010 — the active surveillance era — but this increase disappeared after ...

The prostate inflammation score of biopsy cores is associated with biochemical recurrence risk and might improve prediction of prostate cancer aggressiveness. The degree of inflammation in prostate ...

A 1-year period of intensified androgen receptor blockade prolonged prostate-specific antigen progression-free survival (PSA-PFS) compared with androgen deprivation therapy (ADT) alone for patients ...

Patients who reported current multivitamin use had a lower risk of recurrence than patients who had never taken multivitamins. Patients with prostate cancer may have a lower risk of recurrence if they ...

XTANDI: the first and only androgen receptor inhibitor-based regimen to demonstrate overall survival benefit in non-metastatic hormone-sensitive prostate cancer (nmHSPC) with high-risk biochemical ...

The anti-cancer drug olaparib may be effective in treating biochemically recurrent prostate cancer without accompanying hormone therapy for men who have mutations in genes such as BRCA2, according to ...

CLEVELAND, Ohio (Ivanhoe Newswire) - After skin cancer, prostate cancer is the most common cancer in men in the US. For the men who have beat prostate cancer once, 20 to 30 percent will show signs of ...

Effect of enzalutamide on anticoagulant therapy with edoxaban in patients with prostate cancer. This is an ASCO Meeting Abstract from the 2025 ASCO Genitourinary Cancers Symposium. This abstract does ...

After skin cancer, prostate cancer is the most common cancer in men in the US. For the men who have beat prostate cancer once, 20 to 30 percent will show signs of recurrence after the five-year mark ...